Description
Telmisign (Telmisartan) 40 mg
Telmisign 40 mg is a telmisartan-containing medicine. Telmisartan is an angiotensin II receptor blocker (ARB) used to treat hypertension and to reduce cardiovascular risk in selected patients, depending on the approved product label.
Active Ingredient and Medicine Class
The verified active ingredient is telmisartan, a selective angiotensin II type 1 (AT1) receptor antagonist in the ARB class.
Established Medical Uses
Official prescribing information identifies telmisartan tablets for the treatment of hypertension, with blood-pressure lowering expected to reduce the risk of fatal and nonfatal cardiovascular events. Some regulatory labels also include cardiovascular risk reduction in specific adult populations.
How It Works
Telmisartan blocks angiotensin II from binding to AT1 receptors. This helps relax blood vessels and lowers blood pressure. Clinical reviews describe sustained 24-hour blood-pressure control consistent with telmisartan’s long duration of action.
Important Safety Information
Telmisartan is contraindicated in patients with known hypersensitivity to telmisartan or any component of the product, and it should not be used during pregnancy because medicines that act on the renin-angiotensin system can injure or kill the developing fetus. Important precautions include hypotension, impaired kidney or liver function, and hyperkalemia. Telmisartan should not be combined with aliskiren in patients with diabetes, and concomitant use with an ACE inhibitor is generally avoided because dual renin-angiotensin system blockade increases risk. NSAIDs may reduce the antihypertensive effect and increase renal risk.
Possible Side Effects
Commonly reported adverse effects include back pain, sinusitis, and diarrhea. More serious reactions can include low blood pressure, worsening kidney function, high potassium levels, and rare allergic reactions such as angioedema.
Scientific Evidence
PubMed-indexed reviews and clinical summaries report that telmisartan lowers blood pressure effectively in patients with hypertension and provides sustained control across the dosing interval. Published evidence also supports overall tolerability similar to other ARBs, with established use as an antihypertensive agent.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / FDA: Telmisartan Tablets, Prescribing Information. View source
- Sharpe M, et al. Telmisartan: a review of its use in hypertension. Drugs. 2001. PubMed